The cerebellum forms a highly ordered and indispensible component of motor function within the adult neuraxis, consisting of several distinct cellular subtypes. Cerebellar disease, through a variety of genetic and acquired causes, results in the loss of function of defi ned subclasses of neurons, and remains a signifi cant and untreatable health care burden. The scarcity of therapies in this arena can partially be explained by unresolved disease mechanisms due to inaccessibility of human cerebellar neurons in a relevant experimental context where initiating disease mechanisms could be functionally elucidated, or drug screens conducted. In this review we discuss the potential promise of human induced pluripotent stem cells (hiPSCs) for regenerative neurology, with a particular emphasis on in vitro modelling of cerebellar degeneration. We discuss progress made thus far using hiPSC-based models of neurodegeneration, noting the relatively slower pace of discovery made in modelling cerebellar dysfunction. We conclude by speculating how strategies attempting cerebellar diff erentiation from hiPSCs can be refi ned to allow the generation of accurate disease models. This in turn will permit a greater understanding of cerebellar pathophysiology to inform mechanistically rationalised therapies, which are desperately needed in this fi eld.
Introduction
The cerebellum, also termed ' little brain ' , is an extensively researched part of the neuraxis. Nonetheless, the molecular pathogenesis underlying cerebellar disease remains poorly understood, with the vast majority of such disorders still being immedicable to date (Manto, 2008) . As one of the more principal neuraxial structures with high cellular and structural complexity, the cerebellum integrates and orchestrates ∼ 80% of the number of total CNS neurons in only 10% of the total volume (Azevedo et al., 2009) . Its anatomical location in the posterior cranial fossa is functionally related to coordinating the major input from pontine and vestibular nuclei, the inferior olive and spinal cord to the cerebellum ' s major output pathways via the ventrolateral S. Wiethoff et al. J Neurogenetics, 2015; 29(2-3) : [95] [96] [97] [98] [99] [100] [101] [102] not only directed diff erentiation of any human cell type to model disease in a highly reductionist fashion but also that these cells will express mutations at a normal pathophysiological level, removing the need for artifi cial overexpression, knockdown or knockout. Furthermore, given their theoretically limitless potential to proliferate before directed diff erentiation into clinically relevant cell types, this ' renewable ' resource for experimental material both recapitulates disease phenotypes and further enables high-throughput drug screening in search of a revertive therapeutic agent Malik et al., 2014; Yang et al., 2013) . A second more long-term promise of hiPSCs will be patient-targeted individual therapy through transplantation, although accurate restoration of circuit integrity and function after damage will be a formidable task.
The advent of hiPSCs is of particular relevance to a structure like the cerebellum both from developmental and clinical neurological perspectives as most of the mysteries remain to be unravelled (Manto, 2008; Leiner, 2010; Voogd, 2014) and no cure is available for the treatment of the vast majority of cerebellar diseases. Against this background, understanding the developmental ' logic ' of cerebellar diff erentiation is essential to fi rst permit reproducible directed diff erentiation of hiPSCs in vitro, in order to generate accurate disease models for a variety of cerebellar disorders.
Here we highlight the promise of iPSC technology to regenerative medicine, and especially neurology with a specifi c focus on the cerebellum. We fi rst discuss the prospects and remaining challenges of iPSC technology before focussing specifi cally on current strategies, achievements and limitations for directed diff erentiation to cerebellar neurons. We conclude by summarising the advances in modelling human cerebellar degeneration using hiPSCs and speculating on future areas of interest at the experimental interface between cerebellar neurology and human stem cell-based disease modelling ' in-a-dish ' .
iPSC technology and its relevance to medicine
The discovery of effi cient reprogramming of adult human fi broblasts into iPSCs in 2007 (Takahashi et al., 2007) has since caused a fundamental paradigm shift in regenerative medicine. Subsequent technique optimisation and refi nement of reproducibility and scalability (Okita et al., 2011; Schlaeger et al., 2015; Yu et al., 2009; Jiang et al., 2013; Hou et al., 2013; Warren et al., 2010) have only reinforced the importance of hiPSC-based modelling. With the help of a small number of transgenes it is becoming a standardised procedure to revert primary somatic cells of diseased patients and healthy control individuals into iPSCs for many laboratories worldwide, indeed this technology has also attracted considerable (and growing) commercial interest. These reprogramming methods somewhat circumvent ethical concerns accompanied by the use of primary human embryonic stem cells (hESCs) for medical research, and revolutionise predating approaches including somatic nuclear transfer into oocytes or fusion with ESCs, leading to tetraploidy (Yamanaka & Blau, 2010) . The theoretically endless capability of self-renewal and the preserved genetic background (where mutated genes are expressed at a representative pathophysiological level) render hiPSCs an unprecedented and unparalleled resource. Combined with ongoing advances in the fi eld of directed diff erentiation into disease-specifi c cell types (Tabar & Studer, 2014; Shi et al., 2012; Schwartz et al., 2014; Teng et al., 2014; Dimos et al., 2008; Moretti et al., 2010) , hiPSC in vitro models faithfully recapitulate key aspects not only of human development, but also of genetic and sporadic disease that would otherwise be inaccessible for investigation. Thus, and for the fi rst time in regenerative medicine, this technology enables careful temporal interrogation of pathogenic events in a patient-specifi c manner using a fully humanised model, which bypasses the need for artifi cial overexpression, knockdown or knockout (for a schematic, see Figure 1 ).
iPSC technology and its relevance to neurology
Neuronal cells have been amongst the earliest cell types to be generated via reproducible and effi cient diff erentiation protocols from hESCs (Reubinoff et al., 2001; Zhang et al., 2001) and hiPSCs (Shi et al., 2012; Chambers et al., 2009 ). Protocols range from in vitro formation of embryoid bodies exposed to retinoic acid in a stage-specifi c manner, co-culture with neural inducing feeder cells or direct pharmacological inhibition of transforming growth factor (TGF-beta) and bone morphogenetic protein (BMP) signalling performed on a monolayer of stem cells (dual SMAD inhibition). These approaches can reliably induce neural conversion; the resulting precursors can be ' patterned ' using developmentally rationalised morphogenetic cues, and then be terminally diff erentiated into region-specifi c neuronal and glial subtypes.
Although this technology permits modelling of human developmental processes and diseases (Lancaster et al., 2013; Marchetto et al., 2010) in an essentially foetal system (Patani et al., 2012) , an ever growing number of studies confi rm that mutant hiPSCs derived from patients with inherited disease can successfully recapitulate key cellular pathophysiology, including those diseases that are adult onset (Dimos et al., 2008; Israel et al., 2012; Koch et al., 2011; Lee et al., 2009; Sanchez-Danes et al., 2012; Schondorf et al., 2014; Woodard et al., 2014) . In addition to uncovering cellular and molecular pathogenesis in inherited and sporadic conditions (Israel et al., 2012; Sanchez-Danes et al., 2012) hiPSCs can also be used successfully to screen for potential novel therapeutics Bellin et al., 2012; Cooper et al., 2012) or to delineate genetic from non-genetic infl uences driving neuronal disease as demonstrated lately for the case of monogenic twins discordant in their clinical phenotype with Parkinson ' s disease (PD) (Woodard et al., 2014) . While a comprehensive summary of the most important fi ndings from iPSC studies in the fi eld of neurology is beyond the scope of this article, the interested reader is referred to recent reviews on this topic (Xie & Zhang, 2015; Cao et al., 2014; Ross & Akimov, 2014) . Despite this undisputed contribution to understanding development and disease of the human nervous system, remaining caveats include possible oncogene reactivation via reprogramming procedures, uncontrolled epigenetic and genetic modifi cations of generated stem cells and precursors from in vitro culture conditions or undiscovered transgene integration, low-effi ciency and non-directed diff erentiation that might lead to proliferation and teratoma formation in vivo, laborious and expensive culture and experimental settings with high intrinsic biological variability. These will require further optimisation until this technique can realise its full potential for disease modelling, drug discovery and ultimately autologous transplantation, although this remains a much longer term aim with several unresolved issues to date (Tabar & Studer, 2014; Cyranoski, 2013; Grskovic et al., 2011; Ausubel et al., 2011; Frantz, 2012; Schwartz et al., 2012; Kordower et al., 2008) .
What distinguishes cerebellar modelling with iPSCs from the successful modelling of other subregions of the human brain?
Modelling cerebellar disease with hiPSC technology has not yet become a broadly used routine approach and is reported with less frequency compared with other neurological diseases.
Progress in modelling cortical, striatal, midbrain, spinal, peripheral sensory and autonomic nervous system development and disease using human pluripotent stem cells is largely attributable to the presence of established protocols for directed diff erentiation to region specifi c neurons and glia (Shi et al., 2012; Israel et al., 2012; Aubry et al., 2008; Delli Carri et al., 2013; Perrier & Peschanski, 2012; Jeon et al., 2012; Sanchez-Danes et al., 2012; Perrier et al., 2004; Yan et al., 2005; Kriks et al., 2011; Li et al., 2005 Li et al., , 2008 Hu & Zhang, 2009; Patani et al., 2011; Corti et al., 2012; Devlin et al., 2015; Valensi-Kurtz et al., 2010; Chambers et al., 2012; Lee et al., 2012; Pomp et al., 2005) . This clearly fosters the applicability of hiPSCs in clinical research and further paves its way towards translation as refl ected in the number of publications generated in these respective fi elds. Conversely, modelling cerebellar conditions has been hampered by the absence of such robust diff erentiation paradigms. Comparing the number of iPSC publications investigating neurological non-cerebellar disorders to the amount of published work harnessing iPSC technology to study cerebellar pathology we currently observe a strong disequilibrium: (1) the few reports studying cerebellar diseases with iPSC technology (Koch et al., 2011; Eigentler et al., 2013; Hick et al., 2013; Bird et al., 2014) have derived non-cerebellar cells from patients with primarily cerebellar phenotypes, (2) no reported study thus far has reproduced the single published protocol to specify cerebellar-like cells from hiPSCs (Erceg et al., 2012) available at that time.
Why is the cerebellum lagging behind?
An important contribution to the lack of reliable and effi cient cerebellar diff erentiation protocols might certainly come from the rarity of cerebellar diseases. One could argue that simply the medical and socio-economic necessity to generate hiPSC models of cerebellar disorders is lower and therefore orchestrated eff orts of developmental biologists have focussed on deriving more ' deserving ' cell types for more common disorders such as PD and Alzheimer's disease (AD). In these disciplines, signifi cant progress in directed diff erentiation of disease-relevant neurons has been made (Shi et al., 2012; Perrier et al., Figure 1 . iPSC technology has already started to foster the study of the human cerebellum and its pathologies in a patient-specifi c way. Overcoming the current bottleneck of directed diff erentiation will further facilitate the benefi cial eff ects of this technology on the disorders of the cerebellum. Cerebellar Patient taken from Netter ' s Concise Neurology, p.85, Elsevier, Inc. (copyright). 2004; Yan et al., 2005; Kriks et al., 2011) . Even though (hereditary) degenerative conditions of the cerebellum might be less frequent than degenerative conditions of the basal ganglia or cortex, the cerebellum is aff ected in a range of common and rare conditions, including paraneoplastic cerebellar degeneration, alcohol abuse, nutritional defi ciency and rare inherited conditions [dominant and recessive spinocerebellar ataxias (SCAs and ARCAs)]. Moreover, multiple sclerosis -the most common cause for neurological disability in young people of developed countriesfrequently targets the cerebellum, and tumours in the granule cell (medulloblastomas) represent up to 20 -40% of brain tumours in children and young adults (Arseni & Ciurea, 1981; Salero & Hatten, 2007) . Additionally, cerebellar malformations (e.g. Dandy -Walker or Arnold -Chiari malformations, Joubert syndrome and pontocerebellar hypoplasias) are highly disabling both to the aff ected patients and their carers. Currently, we cannot off er treatment to prevent ongoing cerebellar degeneration, and we will not be able to in the near future, unless we understand the molecular and cellular mechanisms underlying human cerebellar degeneration more precisely. The generation of reliable disease models will be crucial to progress in this fi eld. We therefore want to highlight that a deeper mechanistic understanding of cerebellar development will permit establishment of accurate disease models using iPSC technology. Insights into the molecular pathogenesis will in turn allow more mechanistically rationalised approaches to therapy in this arena.
Against this background, it seems plausible that the inherent and notorious developmental complexity of cerebellar cells [and especially Purkinje cells (PCs)] and subsequent diffi culties generating them from human iPSCs have hampered significant progress in this fi eld, despite both early (Salero & Hatten, 2007; Su et al., 2006; Muguruma et al., 2010) and indeed more recent developmental breakthroughs (Muguruma et al., 2015) .
What has been done to study cerebellar diseases using iPSC technology?
At the time of writing, the authors are aware of one publication using hiPSC-derived long-term self-renewing neuroepitheliallike stem (lt-NES) cells from patients with SCA3 to study the cellular pathology of the most common autosomal-dominant degenerative cerebellar disorder (Koch et al., 2011) . Here, the inherent diffi culty and the lack of effi cient in vitro cerebellar diff erentiation protocols are circumvented by studying lt-NES cells. These cells do express a hindbrain-like transcriptional signature with markers usually observed in cells of a ventral anterior hindbrain fate (Koch et al., 2009 ) which transcriptionally (and possibly functionally) approximates these cells to the cerebellum. Using this model, the authors detected neuronspecifi c early aberrant protein processing, aggravated by excitation in SCA3 mutant iPSC neurons, thereby breaking a milestone for the fi eld in modelling late-onset cerebellar disease in a dish (Koch et al., 2011) . Since then, Friedreich ' s ataxia, the most common autosomal recessive cerebellar disorder with additional multisystemic aff ection has been studied through various attempts using iPSC technology. Again, investigators in these studies utilised non-cerebellar cells to study a cellular phenotype (Eigentler et al., 2013; Hick et al., 2013; Bird et al., 2014; Ku et al., 2010) . None of the above studies reported successful utilisation or modifi cation of the -by that time -only published protocol describing cerebellar-like granule cell differentiation from hiPSCs (Erceg et al., 2012) .
In order to explain the lack of studies using patient-derived iPSCs to generate cerebellar cells and study their pathology we need to address the following question:
What do we know about the development of cerebellar cells that might distinguish them from other neuronal cells?
Cerebellar development in humans occurs over a prolonged time span ranging from the early embryonic period to the fi rst postnatal years. It happens in parallel to the development of the forebrain, midbrain, spinal cord and their arising substructures, but follows its own distinct stereotyped pattern. In summary, four basic processes can be delineated: Firstly, the cerebellar primordium forms at the midbrain -hindbrain boundary (MHB) under close transcriptional infl uence of the isthmic organiser (IsO; for more information on this structure, see, Wurst & BallyCuif, 2001 ). Subsequently, two diff erent proliferative compartments appear, giving rise to two distinct principal cerebellar cell type precursors, which will later migrate and/or diff erentiate to form the inhibitory PCs and the excitatory granule cells. In a third step, the aforementioned granule precursors migrate tangentially to form the external granule layer (EGL) where signifi cant maturation takes place before they eventually migrate radially inwards to their ultimate residence in the internal granule layer (IGL). Finally, cell maturation and establishment of cellular connections characterise the last process giving rise to the three-layered cerebellar cortex with its distinct circuitry and conserved foliation pattern that organises the cerebellum into 10 lobules (for more detailed information on cerebellar development, please see, Ten Donkelaar & Lammens, 2009; White & Sillitoe, 2013) . It is noteworthy that the cerebellar cortex is connected to the remaining neuraxis only via long projecting axons arising from PC somata in the central PC layer, which exert modulatory inhibitory input to deep cerebellar nuclei (DCN).
What do we know about the development of Purkinje cells that might distinguish them from other cerebellar cells?
PCs are not only the cerebellum ' s key eff ectors but they are also thought to be primarily aff ected in SCAs (Hekman & Gomez, 2015) among other cerebellar conditions. Their pronounced sensitivity, morphology, and unique functional circuitry with neighbouring cells permits a carefully coordinated output, which integrates complex temporal and spatial events at the synapse to long-term depression (LTD), or long-term potentiation (LTP) with precision and fi delity (White & Sillitoe, 2013; Schorge et al., 2010; Buff o & Rossi, 2013) .
Their embryonic origin stems from neural progenitor cells of the cerebellar ventricular zone (Hoshino, 2006; Hibi & Shimizu, 2012) , one of the two germinal layers of the cerebellar primordium. However, it has been intrinsically diffi cult for developmental biologists to infl uence PC generation either in vivo or in vitro. Although publication bias towards positive fi ndings confounds an accurate and comprehensive analysis of past and current attempts at cerebellar neurogenesis, one notable recent study demonstrates successful transplantation of cerebellar neural stem cells (NSC) into the cerebellum of SCA3 mutant mice with functional reorganisation (Mendonca et al., 2015) . This report confi rmed a reduction of mutant ataxin-3 (ATXN3) inclusions and atrophy within the cellular layers of the cerebellum and specifi c preservation of the number of PCs post-transplant compared with the non-transplanted mutant mice. Importantly this work failed to demonstrate the specifi cation of PCs from the cerebellar NSC graft in vivo and in vitro, thus suggesting an indirect benefi cial eff ect of the graft on PC survival and cerebellar integrity. The diff erentiation of TUJ1-positive neurons, glial fi brillary acidic protein (GFAP)-positive astrocytes and neural/glial antigen 2 (NG2)-positive oligodendrocytes and their subsequent integration into the cerebellum was observed in vivo and in vitro in their mouse model, at the expense of PCs. These results seem to be somewhat mirrored by the advances in the fi eld of cerebellar cell diff erentiation from hiPSCs: whilst there has been no successful report of mature fully functional PC diff erentiation from hiPSCs or ESCs until early 2015 (Muguruma et al., 2015; Wang et al., 2015) , generation of MATH1 ϩ cerebellar-like granule cells from hiPSCs had been reported years earlier (Erceg et al., 2012) .
How can the fi eld move from here?
The recent publication of Muguruma et al. (2015) is a landmark study recapitulating key developmental steps in cerebellar neurogenesis in order to achieve effi cient directed diff erentiation of hiPSCs. Briefl y, the authors report regionalising ESCderived embryoid bodies to the MHB in vitro and subsequent generation of self-organising cerebellar plate neuroepithelium (CPNE) that gives rise to mature, fully functional PCs and granule cells, as well DCN neurons and various interneurons in specifi c co-culture settings. By the precise timing of sequentially administered extrinsic morphogenetic signals [fi broblast growth factor2 (FGF2), FGF19 and stromal cell-derived factor 1 (SDF1)] the team promoted self-formation of continuous CPNE with dorsal-ventral and apical-basal organisation, mimicking cerebellar development for the fi rst time in a dish. The investigators managed to harness the currently pitted knowledge of developmental cues required for cerebellar development to a reductionist 3D culture with external administration of three morphogens in a timely defi ned manner only. This proof of principle of cerebellar-like development in vitro was conducted on hESCs, although the authors also confi rm that the same protocol applied to two hiPSC lines yielded similar fi ndings (Muguruma et al., 2015) . This study will certainly inspire researchers to reproduce, modify (Wang et al., 2015) and further optimise the protocol (e.g. monolayer culture in fully chemically defi ned medium) and to use this platform to further investigate human cerebellar development and degeneration (see Figure 1) .
The future of iPSC technology in modelling cerebellar diseases
If the above-mentioned goal(s) can be met, the future of modelling cerebellar diseases with iPSC technology will be bright. We are cautiously optimistic that effi cient and reproducible protocols for the generation of PCs and granule cells from hiPSCs will be developed within the coming years using insights from developmental biology and also guided by recent breakthroughs (Koch et al., 2011; Muguruma et al., 2015; Mendonca et al., 2015) . This will be crucially important to foster this currently underrepresented fi eld within hiPSC modelling of neurodegeneration. Such advances will permit accurate study of developmental and degenerative processes. Here, having lagged behind the main fi eld previously might actually become a strategic advantage: important platforms for disease modelling (for recent reviews, please see e.g., Zeng et al., 2014) , drug discovery (e.g., Hunsberger et al., 2015) and evaluation of cell replacement therapies (Kamao et al., 2014) have been established in the meantime successfully for other iPSC-derived cell types, and can be adapted to iPSC-derived cerebellar cells by building on this important knowledge. Successfully applied, these platforms will exert their full potential towards a better understanding of cerebellar development, disease pathways and therapeutic av- Figure 2 . Modelling cerebellar diseases with hiPSC technology: past, present and future. We think, SCA3 and Friedreich ' s ataxia (FA), as the most common autosomal-dominant and -recessive cerebellar degenerative conditions, should be remodelled using PCs diff erentiated from patientderived iPSCs once possible. Furthermore, preferential choice should target cerebellar diseases due to genetic defects in pathophysiologically widely linked genes, e.g. SCA15 (Schorge et al., 2010) , and employ suitable cellular readouts with a focus on electrophysiology and live-cell imaging to widen our knowledge about cerebellar diseases as ' impaired network and impaired plasticity ' disorders. enues in cerebellar disease. We depict this in a time bar summarising past eff orts (blue and black font) with future predictions (red font) which may be of special interest to model genetic cerebellar diseases with iPSC technology (Figure 2) . Furthermore, eff orts in establishing accurate cerebellar in vitro disease models will -as has happened in other fi elds already (Soldner et al., 2011) -be complemented by the generation of isogenic hiPSC lines via modern genomic editing techniques (Hockemeyer et al., 2009 . Such approaches allow introducing or ' correcting ' diff erent mutations that solely aff ect cerebellar integrity against an identical genetic background to precisely disentangle disease-causing mechanisms from background genomic variation between diff erent lines. Finally, the gathered knowledge and progress towards effi cient cerebellar diff erentiation protocols will impact on direct lineage reprogramming eff orts (for recent reviews, please see, Ladewig et al., 2013; Vierbuchen & Wernig, 2012) .
In summary, the cerebellum currently fails to obtain comparable experimental recognition as other neuraxial regions largely due to a poor translation of its underlying developmental biology into directed diff erentiation strategies. Noting recent breakthroughs in the directed diff erentiation of human pluripotent stem cells into cerebellar derivatives, we predict that this hitherto relatively understudied region of the neuraxis can now begin to receive the experimental attention it deserves. This in turn may illuminate the precise mechanisms of cerebellar development and degeneration, thus informing therapeutic strategy.
